Media.Player

Novel Therapeutic Approach for the Treatment of Autism Spectrum Disorders

Detailed Technology Description

Based on these discoveries, the UC San Diego researchers have developed a therapeutic approach for the treatment of autistic spectrum disorder using the targeted delivery of agents that can enable the mutated neuroligin molecule to reach the cell surface and bind effectively to beta-neurexin-1. The invention may have additional applications in the treatment of diseases characterized by abnormal trafficking of adhesion molecules.

Supplementary Information

Patent Number: US7972601B2
Application Number: US2006596160A
Inventor: Taylor, Palmer | Comoletti, Davide | Jennings, Lori | Flynn, Robyn
Priority Date: 11 May 2004
Priority Number: US7972601B2
Application Date: 8 Nov 2006
Publication Date: 5 Jul 2011
IPC Current: A61K003900 | A01N003718 | A61K0039385 | A61K004800 | C07K0014705 | C12N001585 | G01N003368
US Class: 4241851 | 4241921 | 4241941 | 5140013 | 5140177 | 514002 | 514018
Assignee Applicant: The Regents of the University of California
Title: Method of promoting delivery of an antioxidant agent to a cell expression neuroligin
Usefulness: Method of promoting delivery of an antioxidant agent to a cell expression neuroligin
Summary: (M1) is useful for targeting an agent to a cell expressing neuroligin. (M2) is useful for treating an autism spectrum disorder in a subject, where the subject is a mammal, preferably human. A1 or (I) is useful for screening an agent for use in treating autism spectrum disorders, which involves contacting A1 or (I) with the agent, and measuring the amount of neuroligin-3 intracellularly in the treated animals compared to a control (claimed).
Novelty: Targeting agent e.g. sulfur-containing antioxidant such as glutathione, to cell expressing neuroligin, involves linking agent to molecule interacting with binding domain of neuroligin

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

7972601

Others

Intellectual Property Info

See published international patent application (8-Dec-2005; App. 2005/115478).

Related Materials

Comoletti D, De Jaco A, Jennings LL, Flynn RE, Gaietta G, Tsigelny I, Ellisman MH, Taylor P. The Arg451Cys-Neuroligin-3 Mutation Associated with Autism Reveals a Defect in Protein Processing. J Neurosci. 2004 May 19;24(20):4889-93.

Tech ID/UC Case

19657/2004-215-0

Related Cases

2004-215-0

*Abstract

The neuroligins are a family of postsynaptic transmembrane proteins that associate with presynaptic partners, the beta-neurexins. Neurexins and neuroligins play a critical role in initiating formation and differentiation of synaptic junctions. A certain mutation in a neuroligin has been identified in some children with autistic spectrum disorder. By characterizing this neurologin mutation at the biochemical level, UC San Diego researchers have determined that the mutation causes defective neuroligin trafficking, leading to a decrease in the delivery of the mutated neurolgin to the cell surface, and markedly diminished beta-neurexin-1 binding activity.

*IP Issue Date

Jul 5, 2011

*Principal Investigator

Name: Davide Comoletti

Department:

Name: Robyn Flynn

Department:

Name: Lori Jennings

Department:

Name: Palmer Taylor

Department:

Country/Region

USA